ArticleInfection2026
Pathogen patterns in viral ARDS on V-V ECMO: a single-center experience.
Article in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundViral acute respiratory distress syndrome (ARDS) is a common cause of respiratory failure requiring veno-venous extracorporeal membrane oxygenation (V-V ECMO). Pulmonary bacterial superinfections, pulmonary aspergillosis, and viral infections or reactivations frequently occur, but data on their incidence, timing, and microbiological spectrum remain limited. We analyzed infectious complications in a large cohort of V-V ECMO-treated patients with viral ARDS.
methodsWe retrospectively evaluated all patients treated at University Hospital Regensburg (UKR) requiring V-V ECMO for COVID-19 (March 2020-May 2022) or influenza (May 2012-December 2022).
resultsWe included 147 COVID-19 patients (median age 55.3 years; 77% male; SOFA score 9; V-V ECMO duration 23 days) and 72 influenza patients (median age 55.3 years; 53% male; SOFA score 13; V-V ECMO duration 16 days). COVID-19 patients showed higher cumulative incidences of pulmonary bacterial superinfection (61% vs 35%), aspergillosis (33% vs. 22%), CMV reactivation (18%vs. 4%) and HSV reactivation (49% vs. 26%), however incidence-density rates were comparable between groups with incidence rate ratios (IRR) of 1.10, 0.93, 1.36 and 1.12, respectively. First bacterial pulmonary infection occurred a median of 2 days after V-V ECMO initiation in COVID-19 and 1 day before initiation in influenza patients. Predominant bacterial pathogens were Klebsiella spp. (28%), Staphylococcus aureus (27%) and Escherichia coli (11%) in COVID-19, and Staphylococcus aureus (25%) and Streptococcus pneumoniae (25%) in influenza.
conclusionPatients with COVID-19 requiring V-V ECMO showed a distinct trajectory of infectious complications compared to Influenza, particularly bacterial, HSV, CMV, and fungal infections, highlighting their infectious burden.
Indexed as
Identifiers
42455266What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.